OK on Arthritis Test Lifts Hycor Stock 35%
- Share via
(Dow Jones)
Hycor Biomedical Inc.’s stock climbed to a 52-week high Tuesday after the company said it received regulatory approval to market in the U.S. an autoimmune test for rheumatoid arthritis.
The stock, which has gained 400% this year, hit $8.88 before closing at $8.75, up $2.75, or nearly 35%.
Hycor, a Garden Grove maker of diagnostic products, said the test, which was approved by the Food and Drug Administration, can be performed manually or through an automated system.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
